Another DOT1L inhibitor, EPZ-5676, showed promising results in a phase I clinical trial in MLL-rearranged leukemia (Stein et al., 2018) and was validated as ‘orphan drug’ toward MLL-rearranged leukemia by FDA (Cao et al., 2021). This evidence concerns the gene DOT1L and leukemia.